Citations

Clear

815 citation(s) found for "Tang, Yu".

Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases
Haycock, Philip , Burgess, Stephen , Nounu, Aayah , Zheng, Jie , Okoli, George N. , Wade, Kaitlin H. , Timpson, Nicholas J. , Evans, David M. , Willeit, Peter , Aviv, Abraham , Gaunt, Tom R. , Hemani, Gibran , Mangino, Massimo , Ellis, Hayley, Kurian, Kathreena M. , Pooley, Karen A. , Eeles, Rosalind A. , Lee, Jeffrey E. , Fang, Shenying , Chen, Wei V., Law, Matthew H. , Bowdler, Lisa, Iles, Mark M. , Worrall, Bradford B. , Markus, Hugh S. , Hung, Rayjean J., Amos, Chris, Thompson, Deborah J. , O’Mara, Tracy A. , Wolpin, Brian M. , Ámundadóttir, Laufey T. , Trichopoulou, Antonia , Onland‐Moret, N. Charlotte , Lund, Eiliv , Canzian, Federico , Severi, Gianluca , Overvad, Kim , Gunter, Marc J. , ­Tumino, ­Rosario , Svenson, Ulrika, Rij, André van, Baas, Annette F., Bown, Matthew J. , Samani, Nilesh J. , t’Hof, Femke N.G. van, Tromp, Gerard , Jones, Gregory T. , Kuivaniemi, Helena , Elmore, James R. , Johansson, Mattias , McKay, James , Scélo, Ghislaine , Carreras‐Torres, Robert , Gaborieau, Valérie , Brennan, Paul , Bracci, Paige M. , Olson, Sara H. , Gallinger, Steven , Li, Donghui , Petersen, Gloria M. , Han, Jiali , Abnet, Christian C. , Freedman, Neal D. , Aben, Katja K.H. , Kiemeney, Lambertus A. , Vermeulen, Sita H. , Walsh, Kyle M. , Wrensch, Margaret , Rice, Terri, Turnbull, Clare , Litchfield, Kevin , Paternoster, Lavinia , Standl, Marie , Mijatovic, Vladan, Sapkota, Yadav , Zondervan, Krina T. , Nyholt, Dale R. , Heel, David A. van , Arking, Dan E. , Ashar, Foram N., Sotoodehnia, Nona, Woo, Daniel , Comeau, Mary E. , Brown, W. Mark , Silverman, Edwin K. , Hokanson, John E. , Hui, Jennie , Thompson, Philip J. , Morrison, Alanna C. , Smith, Nicholas L. , Christiano, Angela M. , Petukhova, Lynn , Betz, Regina C. , Zhang, Xuejun, Zhu, Caihong, Langefeld, Carl D. , Thompson, Susan D. , Wang, Feijie , Fingerlin, Tasha E. , Rotter, Jerome I. , Cotch, Mary Frances , Jensen, Richard A., Munz, Matthias , Dommisch, Henrik , Schäefer, Arne S. , Ollila, Hanna M. , Hillary, Ryan P. , Zeng, Chenjie , Zheng, Wei , Shu, Xiao-Ou , Reis, André , Uebe, Steffen , Hüffmeier, Ulrike , Kawamura, Yoshiya, Otowa, Takeshi , Sasaki, Tsukasa, Dávila, Sonia , Siminovitch, Katherine A. , Bei, Jin‐Xin , Zeng, Yi‐Xin , Chen, Bowang , Franke, Andre, Fischer, Annegret, Ellinghaus, David , Flores, Carlos , Noth, Imre , Ma, Shwu‐Fan , Foo, Jia Nee , Liu, Jianjun , Cox, David G. , Delattre, Olivier , Mirabeau, Olivier , Skibola, Christine F., Tang, Clara Sze-Man , Garcia-Barceló, Mercè, Su, Wen-Hui , Chang, Yu‐Sun , Wade, Tracey , Lee, Chaeyoung , Kubo, Michiaki , Cha, Pei-Chieng , Nakamura, Yusuke, Levy, Daniel , Hunt, S. E., Spector, Tim D. , Soranzo, Nicole , Barr, R. Graham, Kahali, Bratati , Speliotes, Elizabeth K. , Yerges-Armstrong, Laura M. , Cheng, Ching‐Yu , Wong, Tien Yin , Fogh, Isabella , Powell, John , Rice, Kenneth , Relton, Caroline L. , Martin, Richard M. , Smith, George Davey , Hung, Rayjean J. , Bowden, Jack , Yang, Qiong , Spurdle, Amanda B. , Stolzenberg‐Solomon, Rachael Z. , Duell, Eric J. , Neale, Rachel Ε. , Risch, Harvey A. , Klein, Alison P. , Taylor, Philip R. , Maris, John M. , Wiencke, John K. , Abecasis, Gonçalo R. , SanGiovanni, John Paul , Li, Yong , Low, Siew‐Kee , Montgomery, Grant W. , Hunt, Karen A. , Rosand, Jonathan M. , Cho, Michael H. , Ferreira, Manuel A. R. , Felix, Janine F. , Fan, Xing Hua , Xu, Lin , Schwartz, David A. , Han, Fang , Albagha, Omar , Ralston, Stuart H. , Sasaki, Tsukasa, Hibberd, Martin Lloyd , Xie, Gang , Försti, Asta , Landi, Stefano , Ellinghaus, David , Kim, Jong‐Won , Chang, Kai‐Ping , Martin, Nicholas G. , Gordon, Scott D. , Kimura, Masayuki , Hwang, Shih‐Jen , Manichaikul, Ani , Barr, R. Graham, Jonas, Jost B , Lin, Kuang , Amundadottir, Laufey , Kiemeney, Lambertus A , Eeles, Rosalind A , van Heel, David A , Gunter, Marc J , Canzian, Federico , Hung, Rayjean J , O'Mara, Tracy A , Abnet, Christian C , Haycock, Philip , Tumino, Rosario , Han, Jiali , Martin, Richard M , Severi, Gianluca , Reis, André , Zheng, Wei , Rotter, Jerome I , Carreras-Torres, Robert , Law, Matthew H , Davey Smith, George , Johansson, Mattias , Iles, Mark M , Morrison, Alanna C , Rice, Ken , Freedman, Neal D , Foo, Jia Nee , Levy, Daniel , Rice, Kenneth , Sapkota, Yadav , Wong, Tien Y , Liu, Jing

Mayo Clinic

JAMA Oncology | February 27, 2017 | Volume: 3 | Issue: 5 | Pages: 636

10.1001/jamaoncol.2016.5945 | PMID 28241208 Get It

NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer.
Tang, Gong, Rastogi, Priya , Atkins, James N., Donnellan, Paul , Azar, Catherine A., Robidoux, André, Polikoff, Jonathan, Brufsky, Adam , Biggs, David D., Levine, Edward A. , Zapas, John L., Provencher, Louise , Perez, Edith A. , Costantino, Joseph P., Mamounas, Eleftherios P. , Swain, Sandra M. , Tang, Gong , Geyer, Charles E. , Fehrenbacher, Louis , Paik, Soonmyung , Mamounas, Eleftherios P. , Wolmark, Norman , Brufsky, Adam M , Levine, Edward A

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 30 | Issue: 18_suppl | Pages: LBA1000-LBA1000

10.1200/jco.2012.30.18_suppl.lba1000 Get It

LBA1000 Background: The primary aims were to determine whether adjuvant DD AC→PG will be superior to DD AC→P as well as to TAC in DFS and to compare the relative DFS of TAC and DD AC→P. Secondary endpoints include survival and toxicity. Methods: From Nov 3, 2004 to May 3, 2007, 4894 women were randomized; 1630 to TAC (docetaxel [T] 75 mg/m2, doxorubicin [A] 50 mg/m2, cyclophosphamide [C] 500 mg/m2 q3 wks x 6), 1634 to DD AC→P (A 60 mg/m2 and C 600 mg/m2 q2 wks x 4 followed by P 175 mg/m2 q2 wks x 4), and 1630 to DD AC→PG (A 60 mg/m2 and C 600 mg/m2 q2 wks x 4 → P 175 mg/m2 + G 2000 mg/m2q2 wks x 4). Primary G-CSF support was required and erythropoiesis-stimulating agents (ESA) were used at investigator discretion. 52% were postmenopausal, 65% had 1 - 3 positive nodes, and 80% had HR+ breast cancer. Log-rank tests were used for pair-wise comparisons of the primary (DFS) and secondary (OS) endpoints among the three treatment arms. Results: With 64 months median follow-up, 5-year DFS in DD AC→PG group was 80.6% compared with 82.2% in DD AC→P group (HR=1.1; p=0.27) and 80.1 % (HR=0.97; p=0.71) in TAC group. 5-year OS was 90.8% in DD AC→PG group as compared with 89.1% (HR=.89; p=0.25) in DD AC→P group and 89.6 % (HR=0.90; p=0.32) in TAC group. HR for DFS and OS of DD AC→P vs. TAC were 0.89 (p=0.14) and 1.01 (p=0.92) respectively. Toxicities for TAC, DD AC→P, DD AC→PG, respectively: febrile neutropenia (Gr 3/4: 9%, 4%, 4% [p<0.001]), sensory neuropathy (Gr 3/4: <1%, 7%, 6% [p<0.001]), diarrhea (Gr 3/4: 8 %, 2%, 2% [p<0.001]). Hgb was <10 in 12%, 26%, 33% with ESA use in 35.2%, 47%, 51.6% and transfusions in 3.7%, 6.3%, 9.4%. Deaths on treatment: N=13, 5, 7 (p=0.2). AML/MDS: N=5, 8, 11. All cycles completed in 91% for TAC and 88% for DD regimens. Conclusions: Addition of G to DD AC→P did not improve outcomes. No significant differences in efficacy endpoints were identified between DD AC→P and TAC, though toxicity profiles differed. Funding: NCI PHS U10-CA-37377, -69974, -12027, -69651 and NCCTG U10-CA25224, with additional funding from Eli Lilly & Company, and Amgen, Inc.
Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.
Petrylak, Daniel P. , Tang, Shande, Zhang, Hui , Hamid, Oday , Walgren, Richard A., Tagawa, Scott T. , Kohli, Manish , Kauh, John Sae Wook , N., Kim

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 7_suppl | Pages: 295-295

10.1200/jco.2015.33.7_suppl.295 Get It

295 Background: Patients (pts) with metastatic urothelial carcinoma (UC) progressing after first-line chemotherapy have limited treatment options. Ramucirumab (Ram), a human VEGFR2-targeted mAb, has demonstrated clinical activity in several solid tumors. Preclinical testing supports a role for Ram-taxane combinations in UC. Study JCDC is an open-label, multicenter, randomized phase 2 study of docetaxel (Doc) alone or combined with Ram or icrucumab (Icr) in locally advanced or metastatic platinum-resistant UC. We report on a planned interim analysis for Doc + Ram vs Doc; Icr results will be reported later. Methods: Eligible pts with advanced UC and ECOG PS 0-1 who relapsed ≤ 1 year from a platinum-regimen were randomized to receive Doc 75 mg/m2IV alone or with Ram 10mg/kg IV on Day 1 of repeating 21-day cycles. A sample size of 46 pts per arm enabled 71% power to demonstrate statistical significance of 4.5 mo (Doc + Ram) vs 3 mo (Doc) at a 1-sided α= 0.1. Treatment continued until disease progression or unacceptable toxicity. The primary endpoint is investigator-assessed PFS with RECIST v1.1, analyzed by K-M methods. A planned interim analysis was performed after 75% of the PFS events. Results: 44 pts received Doc and 46 received Doc + Ram. Study arms were well matched with a mean age of 67 yr (29-84), and a 4:1 male to female ratio. 58.7% (Doc + Ram) vs 61.4% (Doc) had ECOG PS 1. 58.7% (Doc + Ram) vs 52.3% (Doc) had visceral metastases. Doc + Ram reduced the risk of disease progression, stratified HR = 0.388; 95% CI: 0.222, 0.677; log-rank p = 0.0005, improving median PFS (5.1 vs 2.4 mo). The ORR for Doc + Ram was 19.6 vs 4.5% for Doc (p= 0.0502), and the disease control rate was 67.4 vs 43.2%. OS maturity is pending. The most common adverse events in the Doc + Ram arm (all grades) were fatigue (80.4% Doc + Ram v 75.0% Doc), decreased appetite (54.3 v 43.2%), nausea (54.3 v 25.0%), and neuropathy (50.0 v 38.6%). Grade (G) ≥3 febrile neutropenia (19.6 v 11.4%), pneumonia (13 v 9.1%), hypertension (4.3 v 0%) were higher with Doc + Ram. One G3 hematuria was observed in each arm. Conclusions: Results support a statistically significant improvement in PFS for Doc + Ram in second-line UC. Final results are expected in 2015. Clinical trial information: NCT01282463.
Trinucleotide Repeat Expansion in the Transcription Factor 4 ( TCF4 ) Gene Leads to Widespread mRNA Splicing Changes in Fuchs' Endothelial Corneal Dystrophy
Wieben, Eric D. , Aleff, Ross A., Tang, Xiaojia , Butz, Malinda L., Kalari, Krishna R. , Highsmith, Edward W., Jen, Jin , Vasmatzis, George , Patel, Sanjay V. , Maguire, Leo J., Baratz, Keith H. , Fautsch, Michael P. , Kalari, Krishna R , Patel, Sanjay V , Tang, Xiaojia

Mayo Clinic

Investigative Opthalmology & Visual Science | January 24, 2017 | Volume: 58 | Issue: 1 | Pages: 343

10.1167/iovs.16-20900 | PMID 28118661 Get It

Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells
Fan, Wei , Yang, Heping , Liu, Ting , Wang, Jiaohong, Li, Tony W.H., Mavila, Nirmala , Tang, Yuanyuan , Yang, JinWon, Peng, Hui , Tu, Jian , Annamalai, Alagappan, Noureddin, Mazen , Krishnan, Anuradha , Martínez‐Chantar, Maria Luz , Mato, José M. , Lu, Shelly C. , Gores, Gregory J. , Lu, Shelly C.

Mayo Clinic

Hepatology | December 17, 2016 | Volume: 65 | Issue: 4 | Pages: 1249-1266

10.1002/hep.28964 | PMID 27981602 Get It

Prohibitin 1 (PHB1) is best known as a mitochondrial chaperone, and its role in cancer is conflicting. Mice lacking methionine adenosyltransferase α1 (MATα1) have lower PHB1 expression, and we reported that c‐MYC interacts directly with both proteins. Furthermore, c‐MYC and MATα1 exert opposing effects on liver cancer growth, prompting us to examine the interplay between PHB1, MATα1, and c‐MYC and PHB1's role in liver tumorigenesis. We found that PHB1 is highly expressed in normal hepatocytes and bile duct epithelial cells and down‐regulated in most human hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). In HCC and CCA cells, PHB1 expression correlates inversely with growth. PHB1 and MAT1A positively regulate each other's expression, whereas PHB1 negatively regulates the expression of c‐MYC, MAFG, and c‐MAF. Both PHB1 and MATα1 heterodimerize with MAX, bind to the E‐box element, and repress E‐box promoter activity. PHB1 promoter contains a repressive E‐box element and is occupied mainly by MAX, MNT, and MATα1 in nonmalignant cholangiocytes and noncancerous tissues that switched to c‐MYC, c‐MAF, and MAFG in cancer cells and human HCC/CCA. All 8‐month‐old liver‐specific Phb1 knockout mice developed HCC, and one developed CCA. Five‐month‐old Phb1 heterozygotes, but not Phb1 flox mice, developed aberrant bile duct proliferation; and one developed CCA 3.5 months after left and median bile duct ligation. Phb1 heterozygotes had a more profound fall in the expression of glutathione synthetic enzymes and higher hepatic oxidative stress following left and median bile duct ligation. Conclusion: We have identified that PHB1, down‐regulated in most human HCC and CCA, heterodimerizes with MAX to repress the E‐box and positively regulates MAT1A while suppressing c‐MYC, MAFG, and c‐MAF expression; in mice, reduced PHB1 expression predisposes to the development of cholestasis‐induced CCA. (Hepatology 2017;65:1249‐1266).
Abstract B63: An effective new strategy to control and inhibit the “undruggable” oncogenic K-RAS hyperactivation in human pancreatic cancer
Bian, Minglei, Zheleva, Vasilena, Njogu, Monicah M., Odanga, Justin J. , Perry, Roger R , Tang, Amy , Hoefer, Richard A. , Knudsen, Bruce E.

Mayo Clinic

Cancer Research | December 15, 2016 | Volume: 76 | Issue: 24_Supplement | Pages: B63-B63

10.1158/1538-7445.panca16-b63 Get It

Abstract Hyperactive K-RAS signaling is a major menace that drives aggressive cancer cell dissemination, tumor progression and metastasis in human pancreatic cancer. Currently, there are no effective therapies to control human pancreatic cancers that have metastasized and oncogenic K-RAS mutations reman “undruggable” in the clinics. Therefore, counteracting K-RAS hyperactivation in attempt to reverse malignant transformation and inhibit latent tumor spread is an important goal in pancreatic cancer biology and major challenge in targeted therapy development in pancreatic cancer. Instead of targeting an upstream signaling module such as EGFR/K-RAS/B-RAF/MEK/MAPK/ERK/AKT/mTOR, we targeted the most downstream signaling module in the K-RAS signaling pathway called the SIAH-dependent proteolytic machinery. SIAHs are the human homologs of Seven-In-Absentia (SINA), an evolutionarily conserved RING E3 ligase, an essential downstream signaling module and a critical “gatekeeper” required for proper K-RAS signal transduction. Guided by studies in Drosophila, SIAH (seven-in-absentia homologue), the most downstream gatekeeper required for proper RAS signaling and tumor cell survival, was identified as a suitable and new drug target for anti-K-RAS and anticancer therapy. We found that inhibiting SIAH function is highly effective to abolish well-established and late-stage pancreatic tumor growth and metastasis in our pre-clinical studies. Thus, we have identified a new vulnerability, SIAH E3 ligase, in the oncogenic K-RAS signaling pathway in pancreatic cancer. These findings demonstrate that SIAH is indeed an attractive, logical and potent anti-K-RAS therapeutic target for us to develop new and effective anticancer strategy against human pancreatic cancer. Through our work, SIAH has emerged as a new and effective drug target against oncogenic K-RAS hyperactivation in human pancreatic cancer. As one of the most evolutionarily conserved E3 ligases, SIAH is ideally and logically positioned to become a next-generation anti-K-RAS drug target in human pancreatic cancer. Our preclinical results have demonstrated that “SIAH-dependent proteolysis” is indeed an Achilles’ heel for human pancreatic cancer cells. Hence, anti-SIAH-based small molecule inhibitors may aid in expanding our arsenal of novel anticancer therapies in pancreatic cancer. By attacking the most downstream “gatekeeper” critical for the proper oncogenic K-RAS signaling transmission, we may be in a position to halt the genesis, progression and metastasis of the most aggressive and the deadliest forms of human pancreatic cancer in the future. We aim to translate these exciting findings to the cancer clinics to benefit our pancreatic cancer patients with metastatic diseases in the future. Citation Format: Amy H. Tang, Minglei Bian, Vasilena Zheleva, Monicah M. Njogu, Justin J. Odanga, Roger R. Perry, Richard A. Hoefer, Bruce E. Knudsen.{Authors}. An effective new strategy to control and inhibit the “undruggable” oncogenic K-RAS hyperactivation in human pancreatic cancer. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr B63.
Vascularized appendicular lymph node transfer for treatment of extremity lymphedema: A case report
Ciudad, Pedro , Manrique, Oscar J. , Date, Shivprasad , Chang, Wei‐Ling , Nicoli, Fabio , Sapountzis, Stamatis , Cheng, Hsu‐Tang , Agko, Mouchammed , Chen, Hung‐Chi , Roberts, Lewis R. , Chen, Hung‐Chi , Roberts, Lewis R , Cheng, Hsu-Tang , Mouchammed, Agko

Mayo Clinic

Microsurgery | December 2, 2016 | Volume: 38 | Issue: 5 | Pages: 553-557

10.1002/micr.30134 | PMID 27911477 Get It

AbstractVascularized lymph node transfer has demonstrated promising results for the treatment of extremity lymphedema. In an attempt to find the ideal donor site, several vascularized lymph nodes have been described. Each has a common goal of decreasing morbidity and avoiding iatrogenic lymphedema while obtaining good clinical results. Herein, we present the preliminary clinical outcomes of an intra‐abdominal lymph node flap option based on the appendicular artery and vein used for the treatment of extremity lymphedema. A 62 year‐old woman with moderate lower extremity lymphedema, on chronic antibiotics because of recurrent infections and unsatisfactory outcomes after conservative treatment underwent a vascularized appendicular lymph node (VALN) transfer. At a follow‐up of 6 months, the reduction rate of the limb circumference was 17.4%, 15.1%, 12.0% and 9% above the knee, below the knee, above the ankle and foot respectively. In addition, no further episodes of infection or other complications were reported after VALN transfer. Postoperative lymphoscintigraphy demonstrated that the VALN flap was able to improve the lymphatic drainage of the affected limb. According to our findings, the use of VALN transfer minimizes donor‐site morbidity, avoids iatrogenic lymphedema and may provide a strong clearance of infection because of the strong immunologic properties of the appendiceal lymphatic tissue in selected patients. Despite these promising results, further research with larger number of patients and longer follow‐ up is needed.
Circular RNAs and their associations with breast cancer subtypes
Nair, Asha, Niu, Nifang, Tang, Xiaojia , Thompson, Kevin J. , Wang, Liewei , Kocher, Jean‐Pierre , Subramanian, Subbaya , Kalari, Krishna R. , Nair, Asha A, Thompson, Kevin J , Kalari, Krishna R , Tang, Xiaojia

Mayo Clinic

Oncotarget | November 5, 2016 | Volume: 7 | Issue: 49 | Pages: 80967-80979

10.18632/oncotarget.13134 | PMID 27829232 Get It

Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression
Tang, Chih-Min, Lee, Tracy E., Syed, Sabriya A. , Burgoyne, Adam M. , Leonard, Stephanie Y., Chan, Jonathan C., Shi, Eileen, Chmielecki, Juliann , Morosini, Deborah, Wang, Kai , Kendrick, Michael L. , Bardsley, Michael R., Siena, Martina De , Mao, Junhao , Ördög, Tamás , Gao, Fei , Ross, Jeffrey S , Harismendy, Olivier , Sicklick, Jason Keith , De Siena, Martina

Mayo Clinic

Oncotarget | October 26, 2016 | Volume: 7 | Issue: 48 | Pages: 78226-78241

10.18632/oncotarget.12909 | PMID 27793025 Get It